RSL3-treated mice also had an obvious lower level of NRF2 protein than DMSO treated group in tumor cell xenografts (Figure 4C,D), shown by both Western blot and immunohistochemistry results, which was also true for NRF2-targeting genes in vivo (Figure 4E). The gene discussed is NFE2L2; the disease is neoplasm.